www.vuitypro.com Open in urlscan Pro
2600:9000:211e:8a00:5:8ced:94c0:93a1  Public Scan

Form analysis
0 forms found in the DOM

Text Content

 * For U.S. Healthcare Professionals Only
 * Patient Website
 * Full Prescribing Information

Register for a Live Program






For US Healthcare Professionals Only






FIRST AND ONLY

FDA-approved eye drop specifically designed for presbyopia in adults.1,2

Reengineered formulation
of pilocarpine delivered with

pHastTM technology

Rapidly adjusts to physiologic pH*2

*In vitro data. Clinical significance is unknown. The pH range in the bottle is
between 3.5 and 5.5.1



Improved

Near and Intermediate Vision

without compromising distance vision1

Primary endpoint was ≥3-line in mesopic, high-contrast, binocular
distance-corrected near visual acuity (DCNVA) without losing more than 1 line (5
letters) of corrected distance visual acuity (CDVA) with the same refractive
correction at Day 30, Hour 3.1

Change from baseline in photopic, high-contrast, binocular distance-corrected
intermediate visual acuity (DCIVA) at Day 30, Hour 3 was a prespecified
secondary endpoint.3

Designed to balance

Efficacy, Safety, and Tolerability1,2




CAN’T WAIT TO LEARN MORE?

Register to be the first to know when VUITY™ becomes available.



References: 1. VUITY Prescribing Information. 2. Price FW, et al. Ophthalmol
Sci. 2021; doi: https://doi.org/10.1016/j.xops.2021.100065 3. Data on File,
ABBVTTRI73127.




INDICATION

VUITY™ (pilocarpine hydrochloride ophthalmic solution) 1.25% is indicated for
the treatment of presbyopia in adults.


IMPORTANT SAFETY INFORMATION


CONTRAINDICATIONS

VUITY is contraindicated in patients with known hypersensitivity to any
ingredient in the formulation.


WARNINGS AND PRECAUTIONS

Patients should be advised to exercise caution in night driving and other
hazardous occupations in poor illumination. In addition, miotics may cause
accommodative spasm. Patients should be advised not to drive or use machinery if
vision is not clear.

Rare cases of retinal detachment have been reported with other miotics when used
in susceptible patients and those with pre-existing retinal disease. Patients
should be advised to seek immediate medical care with sudden onset of vision
loss.

VUITY is not recommended to be used when iritis is present because adhesions
(synechiae) may form between the iris and lens.

Contact lens wearers should be advised to remove their lenses prior to the
instillation of VUITY and to wait 10 minutes after dosing before reinserting
their contact lenses.

To prevent eye injury or contamination, care should be taken to avoid touching
the dispensing bottle to the eye or to any other surface.


ADVERSE REACTIONS

The most common adverse reactions (>5%) reported in clinical trials were
headache and conjunctival hyperemia.

Please see full Prescribing Information.

US-PBY-210241


 * Contact Us
 * Terms of Use
 * Privacy Policy

VUITY™ and its design are registered trademarks of Allergan, Inc., an AbbVie
company. All other trademarks are the property of their respective owners. ©
2021 AbbVie. All rights reserved. This information is intended for US healthcare
professionals only.

US-VUI-210112











IMPORTANT SAFETY INFORMATION


CONTRAINDICATIONS

VUITY is contraindicated in patients with known hypersensitivity to any
ingredient in the formulation.


WARNINGS AND PRECAUTIONS

Patients should be advised to exercise caution in night driving and other
hazardous occupations in poor illumination. In addition, miotics may cause


IMPORTANT SAFETY INFORMATION


CONTRAINDICATIONS

VUITY is contraindicated in patients with known hypersensitivity to any
ingredient in the formulation.


WARNINGS AND PRECAUTIONS

Patients should be advised to exercise caution in night driving and other
hazardous occupations in poor illumination. In addition, miotics may cause


IMPORTANT SAFETY INFORMATION


CONTRAINDICATIONS

VUITY is contraindicated in patients with known hypersensitivity to any
ingredient in the formulation.


WARNINGS AND PRECAUTIONS

Patients should be advised to exercise caution in night driving and other
hazardous occupations in poor illumination. In addition, miotics may cause


IMPORTANT SAFETY INFORMATION


CONTRAINDICATIONS

VUITY is contraindicated in patients with known hypersensitivity to any
ingredient in the formulation.


WARNINGS AND PRECAUTIONS

Patients should be advised to exercise caution in night driving and other
hazardous occupations in poor illumination. In addition, miotics may cause


INDICATION

VUITY™ (pilocarpine hydrochloride ophthalmic solution) 1.25% is indicated for
the treatment of presbyopia in adults.


IMPORTANT SAFETY INFORMATION


CONTRAINDICATIONS

VUITY is contraindicated in patients with known hypersensitivity to any
ingredient in the formulation.


WARNINGS AND PRECAUTIONS

Patients should be advised to exercise caution in night driving and other
hazardous occupations in poor illumination. In addition, miotics may cause
accommodative spasm. Patients should be advised not to drive or use machinery if
vision is not clear.

Rare cases of retinal detachment have been reported with other miotics when used
in susceptible patients and those with pre-existing retinal disease. Patients
should be advised to seek immediate medical care with sudden onset of vision
loss.

VUITY is not recommended to be used when iritis is present because adhesions
(synechiae) may form between the iris and lens.

Contact lens wearers should be advised to remove their lenses prior to the
instillation of VUITY and to wait 10 minutes after dosing before reinserting
their contact lenses.

To prevent eye injury or contamination, care should be taken to avoid touching
the dispensing bottle to the eye or to any other surface.


ADVERSE REACTIONS

The most common adverse reactions (>5%) reported in clinical trials were
headache and conjunctival hyperemia.

Please see full Prescribing Information.

US-PBY-210241